卫材(ESALY.US)合作方重磅药仑卡奈单抗欧洲上市遇阻

智通财经网07-27

智通财经APP获悉，7月26日，卫材(ESALY.US)合作方BioArctic公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)不建议批准仑卡奈单抗(Lecanemab)上市。当天，BioArctic迅速与卫材进行了沟通，后者表示将与CHMP进行沟通，要求其重新审查给出的负面意见。按照规定，卫材可以在60天内提出复审申请，而CHMP也将在60天内给予回复。仑卡奈单抗是BioArctic...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2454053104?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-27 16:33","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2454053104","market":"sg","top_or_hot":-1,"title":"卫材(ESALY.US)合作方重磅药仑卡奈单抗欧洲上市遇阻","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，7月26日，卫材(ESALY.US)合作方BioArctic公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)不建议批准仑卡奈单抗(Lecanemab)上市。当天，BioArctic迅速与卫材进行了沟通，后者表示将与CHMP进行沟通，要求其重新审查给出的负面意见。按照规定，卫材可以在60天内提出复审申请，而CHMP也将在60天内给予回复。仑卡奈单抗是BioArctic...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1156481.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>卫材(ESALY.US)合作方重磅药仑卡奈单抗欧洲上市遇阻</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n卫材(ESALY.US)合作方重磅药仑卡奈单抗欧洲上市遇阻\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-27 16:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1156481.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，7月26日，卫材(ESALY.US)合作方BioArctic公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)不建议批准仑卡奈单抗(Lecanemab)上市。当天，BioArctic迅速与卫材进行了沟通，后者表示将与CHMP进行沟通，要求其重新审查给出的负面意见。按照规定，卫材可以在60天内提出复审申请，而CHMP也将在60天内给予回复。仑卡奈单抗是BioArctic...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1156481.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHMP","symbol_name":"冠军工业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1156481.html","article_id":"2454053104","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454053104","pubTimestamp":1722069191,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，7月26日，卫材合作方BioArctic公司宣布欧洲药品管理局人用药品委员会不建议批准仑卡奈单抗上市。当天，BioArctic迅速与卫材进行了沟通，后者表示将与CHMP进行沟通，要求其重新审查给出的负面意见。仑卡奈单抗是BioArctic开发的一种抗β淀粉样蛋白(Aβ)单克隆抗体，可以选择性中和并清除导致阿尔茨海默病神经病变的可溶且有毒性的Aβ聚集体。因此，仑卡奈单抗可能对AD病理过程产生积极影响并减缓疾病发展进程。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CHMP":"冠军工业","BK4087":"商业印刷"},"translate_title":"Eisai (ESALY.US) partner blockbuster drug Lecanemab encounters obstacles to launch in Europe","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHMP":1},"content_text":"智通财经APP获悉，7月26日，卫材(ESALY.US)合作方BioArctic公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)不建议批准仑卡奈单抗(Lecanemab)上市。当天，BioArctic迅速与卫材进行了沟通，后者表示将与CHMP进行沟通，要求其重新审查给出的负面意见。按照规定，卫材可以在60天内提出复审申请，而CHMP也将在60天内给予回复。仑卡奈单抗是BioArctic开发的一种抗β淀粉样蛋白(Aβ)单克隆抗体，可以选择性中和并清除导致阿尔茨海默病神经病变的可溶且有毒性的Aβ聚集体。因此，仑卡奈单抗可能对AD病理过程产生积极影响并减缓疾病发展进程。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454053104"}